125 related articles for article (PubMed ID: 32974155)
1. Loss of HES-1 Expression Predicts a Poor Prognosis for Small Intestinal Adenocarcinoma Patients.
Kim JW; Jun SY; Ylaya K; Chang HK; Oh YH; Hong SM; Chung JY; Hewitt SM
Front Oncol; 2020; 10():1427. PubMed ID: 32974155
[No Abstract] [Full Text] [Related]
2. Prognostic implication of SOX2 expression in small intestinal adenocarcinoma.
Kim JW; Chung JY; Ylaya K; Park Y; Jun SY; Hong SM; Hewitt SM
Virchows Arch; 2021 Jun; 478(6):1049-1060. PubMed ID: 33103210
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
4. Low HES-1 and positive DLL4 expression predicts poor prognosis of colorectal cancers.
Kim G; Jung J; Kim JW; Kim JY
Pathology; 2023 Feb; 55(1):52-57. PubMed ID: 36167746
[TBL] [Abstract][Full Text] [Related]
5. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
6. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
7. Adenocarcinoma of the small intestine: a multi-institutional study of 197 surgically resected cases.
Chang HK; Yu E; Kim J; Bae YK; Jang KT; Jung ES; Yoon GS; Kim JM; Oh YH; Bae HI; Kim GI; Jung SJ; Gu MJ; Kim JY; Jang KY; Jun SY; Eom DW; Kwon KW; Kang GH; Park JB; Hong S; Lee JS; Park JY; Hong SM;
Hum Pathol; 2010 Aug; 41(8):1087-96. PubMed ID: 20334897
[TBL] [Abstract][Full Text] [Related]
8. Loss of CADM4 expression is associated with poor prognosis in small intestinal adenocarcinomas.
Kim KJ; Kim JY; Hong SM; Gu MJ
APMIS; 2017 May; 125(5):437-443. PubMed ID: 28444978
[TBL] [Abstract][Full Text] [Related]
9. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.
Bittoni A; Piva F; Santoni M; Andrikou K; Conti A; Loretelli C; Mandolesi A; Lanese A; Pellei C; Scarpelli M; Principato G; Cascinu S
Future Oncol; 2015; 11(13):1905-17. PubMed ID: 26161927
[TBL] [Abstract][Full Text] [Related]
10. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.
Bournet B; Muscari F; Buscail C; Assenat E; Barthet M; Hammel P; Selves J; Guimbaud R; Cordelier P; Buscail L
Clin Transl Gastroenterol; 2016 Mar; 7(3):e157. PubMed ID: 27010960
[TBL] [Abstract][Full Text] [Related]
11. Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.
Yu HA; Sima CS; Hellmann MD; Naidoo J; Busby N; Rodriguez K; Riely GJ; Kris MG
Cancer; 2015 Jun; 121(12):2078-82. PubMed ID: 25781862
[TBL] [Abstract][Full Text] [Related]
12. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival.
Hartman DJ; Davison JM; Foxwell TJ; Nikiforova MN; Chiosea SI
Int J Cancer; 2012 Oct; 131(8):1810-7. PubMed ID: 22290300
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
14. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and prognostic significance of heme oxygenase-1 expression in small intestinal adenocarcinomas.
Jun SY; Hong SM; Bae YK; Kim HK; Jang KY; Eom DW
Pathol Int; 2018 May; 68(5):294-300. PubMed ID: 29537718
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Hes-1, a downstream target of notch signaling in hepatocellular carcinoma.
Zou JH; Xue TC; Sun C; Li Y; Liu BB; Sun RX; Chen J; Ren ZG; Ye SL
Asian Pac J Cancer Prev; 2015; 16(9):3811-6. PubMed ID: 25987042
[TBL] [Abstract][Full Text] [Related]
17. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
[TBL] [Abstract][Full Text] [Related]
18. Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma.
Ahadi M; Andrici J; Sioson L; Sheen A; Clarkson A; Gill AJ
Hum Pathol; 2016 Nov; 57():91-97. PubMed ID: 27476040
[TBL] [Abstract][Full Text] [Related]
19. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
20. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
